Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.

Description

The Kanteron Platform assimilated a wide array of medical images, digital pathology slides, genomic sequences, and patient information from various modalities, scanners, sequencers, and databases, delivering a comprehensive data toolkit to all teams within hospital networks. It emphasizes pharmacogenomics to avert adverse medication events and facilitates the application of precision medicine at the point of care by integrating data sources on drug-gene interactions that were formerly only accessible in less user-friendly formats, such as tables found in PDF documents. By incorporating major pharmacogenomic databases like PharmGKB, CGI, DGIdb, and OpenTargets, it enables users to customize their queries according to specific gene families, types of interactions, and drug classifications. Additionally, its adaptable AI allows users to select the dataset that best aligns with their specific use case, applying it effectively to pertinent medical images. This robust functionality not only enhances the accuracy of medical insights but also fosters a more personalized approach to patient care.

API Access

Has API No 

API Access

Has API No 

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Customer Support

Business Hours No 
Live Rep (24/7) No 
Online Support Yes 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Types of Training

Training Docs No 
Webinars Yes 
Live Training (Online) No 
In Person No 

Types of Training

Training Docs No 
Webinars No 
Live Training (Online) No 
In Person No 

Vendor Details

Company Name

Bruker

Founded

1960

Country

United States

Website

www.bruker.com/en/applications/pharma/drug-discovery.html

Vendor Details

Company Name

Kanteron Systems

Founded

2005

Country

Spain

Website

www.kanteron.com/platform

Product Features

Product Features

Medical Imaging

Automated Routing No 
Comparison View No 
Compliance Management No 
Data Import / Export No 
Diagnostic Reporting No 
Image Analytics No 
Treatment Planning No 
Workflow Management No 

Alternatives

Alternatives

SILCS Reviews

SILCS

SilcsBio